Clearmind Medicine's CMND-100 has met its primary endpoint of safety and tolerability in Part A of an ongoing Phase 1/2 trial for Alcohol Use Disorder. The study enrolled 24 healthy volunteers across four single-ascending-dose cohorts of approximately 20 mg, 40 mg, 80 mg and 160 mg, with all participants completing treatment according to protocol. No serious adverse events were reported, and overall tolerability remained consistent across all four cohorts. CMND-100 is an oral formulation of 5-methoxy-2-aminoindane, a non-hallucinogenic neuroplastogen-derived compound designed to promote adaptive neuroplasticity without the perceptual effects of classical psychedelics. The multicenter trial is being conducted under FDA oversight at institutions including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Clearmind intends to advance the program into subsequent stages, including dosing patients with Alcohol Use Disorder, following completion of the full Part A dataset analysis.
Clearmind Medicine Inc. Common SharesCMND-100 met primary safety endpoint in Phase 1 trial for Alcohol Use Disorder